European Society of Cardiology Highlights: Late-breaking Trials – COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "European Cardiology Review"
DOI: 10.15420/ecr.2022.03
Abstract: Colchicine: ECLA PHRI COLCOVID Trial The anti-inflammatory effect of colchicine on the cytokine storm made it a promising candidate for the treatment of COVID-19, and the drug is known to be safe and well tolerated.… read more here.
Keywords: society cardiology; cardiology; cardiology highlights; late breaking ... See more keywords
European Society of Cardiology Highlights: Late-breaking Science MINOCA/ANOCA
Sign Up to like & getrecommendations! Published in 2022 at "European Cardiology Review"
DOI: 10.15420/ecr.2022.22
Abstract: increase without percutaneous coronary intervention. During a mean follow-up of 3.4 ± 3.6 years, 3,321 deaths occurred (18.2%). Compared to patients without MI (16.1%), patients with type 1 MI (25.2%) and type 2 MI (29.1%)… read more here.
Keywords: society cardiology; cardiology; cardiology highlights; highlights late ... See more keywords